Showing results (551-560 of 635) with videos related to
Sort By:
Pageof 64
Proceedings of the National Academy of Sciences of the United States of America|September 13, 2006
Testing the importance of p27 degradation by the SCFskp2 pathway in murine models of lung and colon cancerInke Timmerbeul, Carrie M Garrett-Engele, Uta Kossatz, et al.International Journal of Molecular Sciences|August 12, 2022
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World SettingRamona Erber, Miriam Angeloni, Robert Stöhr, et al.Genes, Chromosomes & Cancer|June 6, 2020
Germline SDHB-inactivating mutation in gastric spindle cell sarcomaChristoph E Heilig, Peter Horak, Daniel B Lipka, et al.Lung Cancer (Amsterdam, Netherlands)|July 1, 2026
Prevalence and characteristics of NTRK fusions in 25,946 patients with non-small cell lung cancerTeodora Radonic, Sepehr Rahmani-Khajouei, Urania Dafni, et al.Clinical Chemistry and Laboratory Medicine|August 6, 2026
Unified definition of integrated diagnostics: a position statement of the EFLMJochen K Lennerz, Fabio Del Ben, Albrecht Stenzinger, et al.Laboratory Investigation; a Journal of Technical Methods and Pathology|October 17, 2017
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2βMieke Raap, Malte Gronewold, Henriette Christgen, et al.Cell Reports|September 21, 2018
Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast CancerRoy Z Granit, Hadas Masury, Reba Condiotti, et al.Lung Cancer (Amsterdam, Netherlands)|March 5, 2021
Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical fieldAnna-Lena Volckmar, Petros Christopoulos, Martina Kirchner, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2023
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung CancerPhilip Bischoff, Martin Reck, Tobias Overbeck, et al.Molecular Cancer|January 10, 2024
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based thresholdTim Schmäche, Juliane Fohgrub, Anna Klimova, et al.Pageof 64